BioSpace News Archive

Willow Biosciences Inc. announced today a follow-on engagement with Sandhill One, LLC (www.sandhillone.com) (“Sandhill”) for the next phase in optimizing a proprietary enzyme vital to the development of a large volume Active Pharmaceutical Ingredient (“API”) used in nutraceutical and pharmaceutical products.

GermStopSQ has been issued a Notice of Compliance by Health Canada and granted a Drug Identification Number, making Good Theorem the first to launch a residual* disinfectant that keeps killing 99.999% of bacteria and 99.9% of Human Coronavirus 229E for 24 hours, making it the first of its kind on the market.

TandemAI, a technology company focused on transforming drug discovery infrastructure, today announced the appointment of Alessandro Monge, PhD, as Chief Business Officer.

NEXGEL, Inc. announced today the appointment of Scott Henry, CFA as a new independent director to the Company’s Board of Directors (the “Board”), effective immediately.

Dianthus Therapeutics, a biotechnology company dedicated to advancing the next generation of antibody complement therapeutics, today announced the appointment of Susan Kalled, Ph.D., as Chief Scientific Officer.

Akron Bio (“Akron”), a leading supplier of critical inputs for cell and gene therapies, today announced that Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) has granted Akron Eligibility Confirmation for its cGMP Virus Inactivated Human Fibronectin.

THREAD , the leading technology and consulting service provider enabling electronic clinical outcome assessments (eCOA) and decentralized clinical trials (DCTs), announced today its five-year collaboration with innovative global health care company, Sanofi.

Akadeum Life Sciences Inc. announced today that it will preview its automated platform at Phacilitate’s Advanced Therapies Week, January 17-20th in Miami, Florida.

Theriva Biologics today announced the first patient has been dosed in VIRAGE, the Phase 2b randomized, open-label, placebo-controlled, multicenter clinical trial of systemically administered VCN-01 in combination with standard-of-care (SoC) chemotherapy (gemcitabine/nab-paclitaxel) as a first line therapy for patients with newly-diagnosed metastatic pancreatic ductal adenocarcinoma (PDAC).

NewAmsterdam Pharma Company N.V. (Nasdaq:NAMS) (“NewAmsterdam” or the “Company”) today announced topline results from ROSE2, a Phase 2 clinical trial evaluating obicetrapib, the company’s oral, low-dose and once-daily cholesteryl ester transfer protein (“CETP”) inhibitor, in combination with ezetimibe as an adjunct to high-intensity statin therapy.